TheraRadar
← Back
Data updated: Mar 29, 2026

VALEANT PHARMS NORTH

DermatologyCardiovascular
Pharma

VALEANT PHARMS NORTH is a pharmaceutical company focused on Dermatology, Cardiovascular.

1973
Since
9
Drugs
-
Trials
46
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
VENLAFAXINE HYDROCHLORIDE 2026-01-30
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-24
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-24
Labeling
DILTIAZEM HYDROCHLORIDE 2026-01-18
Labeling
DILTIAZEM HYDROCHLORIDE 2025-11-14
VENLAFAXINE HYDROCHLORIDE 2025-09-17
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Dermatology 50%
1 drugs
Cardiovascular 50%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Baxter specialty
Cardiovascular, Dermatology
Bayer big-pharma
Cardiovascular, Dermatology
B BRAUN specialty
Dermatology, Cardiovascular
BAUSCH specialty
Dermatology, Cardiovascular
COSETTE other
Cardiovascular, Dermatology